In clinical trials of patients who were overweight or obese and had T2DM, liraglutide was found to reduce IL‐6, TNF‐α, sCD163, IL‐1β and IL‐6 [103, 105, 106, 107]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.